NAMI-A


NAMI-A

NAMI-A and KP1019 are two ruthenium anticancer agents that have already entered clinical trials.[1] They belong to the RAPTA series of complexes that have shown potential for the further development of anticancer drugs.[2] NAMI is the acronym for New Anti-tumour Metastasis Inhibitor; -A means that this is the first of a series. RAPTA is the acronym for Ruthenium-Arene-PTA (PTA is 1,3,5-triaza-7-phosphaadamantane).

Ruthenium is a rare noble metal, unknown to living systems, with a strong complex forming ability with numerous ligands.[3] Its partially filled 4d sub-shell allows it to form complexes that are useful for a wide variety of applications including catalysis, electronics, photochemistry, biosensors and anticancer drugs.[4][1] Ruthenium, unlike traditional platinum complexes, shows greater resistance to hydrolysis and more selective action on tumors.

External links

NAMI-A

References

  1. ^ a b Kostova, I., Ruthenium complexes as anticancer agents. Current medicinal chemistry 2006, 13 (9), 1085-1107. doi:10.2174/092986706776360941
    • Lentz, F.; Drescher, A.; Lindauer, A.; Henke, M.; Hilger, R. A.; Hartinger, C. G.; Scheulen, M. E.; Dittrich, C. et al. (2009). "Pharmacokinetics of a novel anticancer ruthenium complex (KP1019, FFC14A) in a phase I dose-escalation study". Anti-Cancer Drugs 20 (2): 97–103. doi:10.1097/CAD.0b013e328322fbc5. PMID 19209025.  edit
  2. ^ Levina, A.; Mitra, A.; Lay, P., Recent developments in ruthenium anticancer drugs. Metallomics 2009, 1 (6), 458-470. doi:10.1039/B904071D
  3. ^ Gopal, Y.; Jayaraju, D.; Kondapi, A., Inhibition of Topoisomerase II Catalytic Activity by Two Ruthenium Compounds: A Ligand-Dependent Mode of Action†. Biochemistry 1999, 38 (14), 4382-4388. doi:10.1021/bi981990s
  4. ^ Antonarakis, E.; Emadi, A., Ruthenium-based chemotherapeutics: are they ready for prime time? Cancer chemotherapy and pharmacology 2010, 66 (1), 1-9. 3. doi:10.1007/s00280-010-1293-1